Suppr超能文献

通过施用EFRH噬菌体对阿尔茨海默氏症β-淀粉样蛋白斑块进行免疫。

Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration.

作者信息

Frenkel D, Katz O, Solomon B

机构信息

Department of Molecular Microbiology and Biotechnology, The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Ramat Aviv, Tel-Aviv 69978, Israel.

出版信息

Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11455-9. doi: 10.1073/pnas.97.21.11455.

Abstract

The epitope EFRH, corresponding to amino acids 3-6 within the human beta-amyloid peptide (AbetaP), acts as a regulatory site controlling both the formation and disaggregation process of the beta-amyloid fibrils (Abeta). Locking of this epitope by highly specific antibodies affects the dynamics of the entire AbetaP molecule, preventing self-aggregation as well as enabling resolubilization of already formed aggregates. Production of such antibodies by repeated injections of toxic human Abeta fibrils into transgenic mice suggests the feasibility of vaccination against Alzheimer's disease. Here, we report the development of an immunization procedure for the production of effective anti-aggregating beta-amyloid antibodies based on filamentous phages displaying the EFRH peptide as specific and nontoxic antigen. Effective autoimmune antibodies were obtained by EFRH phage administration in guinea pigs, which exhibit AbetaP identical to the human AbetaP region. Moreover, because of the high antigenicity of the phage, no adjuvant is required to obtain high affinity anti-aggregating IgG antibodies after a short immunization period of 3 weeks. Availability of such antibodies opens up possibilities for the development of an efficient and long-lasting vaccination for the prevention and treatment of Alzheimer's disease.

摘要

表位EFRH对应于人类β-淀粉样肽(AbetaP)内的第3至6个氨基酸,它作为一个调控位点,控制着β-淀粉样纤维(Abeta)的形成和解聚过程。高特异性抗体对该表位的锁定会影响整个AbetaP分子的动态变化,既能防止自我聚集,又能使已形成的聚集体重新溶解。通过向转基因小鼠反复注射有毒的人类Abeta纤维来产生此类抗体,这表明了针对阿尔茨海默病进行疫苗接种的可行性。在此,我们报告了一种免疫程序的开发,该程序基于展示EFRH肽作为特异性无毒抗原的丝状噬菌体来生产有效的抗聚集β-淀粉样抗体。通过向豚鼠施用EFRH噬菌体获得了有效的自身抗体,豚鼠体内的AbetaP与人AbetaP区域相同。此外,由于噬菌体具有高抗原性,在3周的短免疫期后,无需佐剂就能获得高亲和力的抗聚集IgG抗体。此类抗体的可得性为开发一种高效且持久的用于预防和治疗阿尔茨海默病的疫苗开辟了可能性。

相似文献

3
Towards Alzheimer's beta-amyloid vaccination.迈向阿尔茨海默病β-淀粉样蛋白疫苗
Biologicals. 2001 Sep-Dec;29(3-4):243-7. doi: 10.1006/biol.2001.0294.
5
Filamentous bacteriophage as a novel therapeutic tool for Alzheimer's disease treatment.
J Alzheimers Dis. 2008 Oct;15(2):193-8. doi: 10.3233/jad-2008-15205.
6
Vaccination for the prevention and treatment of Alzheimer's disease.
Drugs Today (Barc). 2000 Sep;36(9):655-63. doi: 10.1358/dot.2000.36.9.593782.

引用本文的文献

本文引用的文献

1
Oral anti-IgE immunization with epitope-displaying phage.用展示表位的噬菌体进行口服抗IgE免疫
Eur J Immunol. 2000 Jan;30(1):128-35. doi: 10.1002/1521-4141(200001)30:1<128::AID-IMMU128>3.0.CO;2-X.
3
Loss of olfactory function in dementing disease.
Physiol Behav. 1999 Apr;66(2):177-82. doi: 10.1016/s0031-9384(98)00262-5.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验